daily pilot
.#1 in news, talk, and sports in los angeles and orange county
.
loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people.
.
submit a letter to the editor
.
despite neutral imaging results, adalimumab did improve other key markers of inflammation in the blood including glyca, crp, tnf, and il-6.
.